Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Latest News
    • Aliskiren added to...

    Aliskiren added to losartan increases hyperkalemia risk in non-diabetic CKD patients

    Written by Medha Baranwal Baranwal Published On 2020-01-13T19:28:01+05:30  |  Updated On 13 Jan 2020 7:28 PM IST
    Aliskiren added to losartan increases hyperkalemia risk in non-diabetic CKD patients

    Hong Kong, China: Aliskiren addition to losartan provides no further renoprotective benefit instead it increases the risk of hyperkalemia in non-diabetic chronic kidney disease (CKD) patients, compared with the use of losartan alone, suggests a recent study.


    Chronic kidney disease, also called chronic kidney failure, is a condition characterized by gradual loss of kidney function. In the early stages of chronic kidney disease, a few signs or symptoms may be evident. CKD may not become apparent until the kidney function is significantly impaired.


    The findings of the study were presented by Sydney C.W. Tang, MD, of the University of Hong Kong, at the American Society of Nephrology’s Kidney Week 2019 meeting. The study was conducted to determine the potential long-term safety and efficacy of aliskiren in non-diabetic CKD.


    For the study, non-diabetic stage 3-4 patients (n=76) were randomized to receive aliskiren added on to losartan (maximally tolerated dose) or losartan alone.


    The primary outcome was the slope of eGFR (estimated glomerular filtration rate) at 3 years, along with other secondary endpoints. Composite renal outcomes of doubling of baseline serum creatinine (sCr) or a 40% reduction in eGFR or incident end-stage renal disease (ESRD) or death was analyzed as post-hoc analysis.


    Read Also: Chronic kidney disease linked to 95% increased risk of heart attack, finds Mayo Clinic study


    Key findings of the study include:




    • After a follow-up of 144 weeks in 76 subjects, there was no difference in the slope of eGFR.

    • 6 patients receiving aliskiren and 7 control patients reached the renal composite endpoint (16.2% vs. 17.9%).

    • Cardiovascular events rate was 10.8% vs. 2.6%.

    • The hyperkalemia rate was 18.9% vs. 5.1%.


    Read Also: Coffee reduces death risk in chronic kidney disease patients


    "Compared to losartan alone, add-on aliskiren conferred no further renoprotective benefit but increased hyperkalemia risks in non-diabetic CKD patients," concluded the authors.



    The study, "A Phase 3 Randomized Controlled Trial on the Effect of Losartan vs. Add-On Aliskiren in CKD," was presented at the American Society of Nephrology’s Kidney Week 2019 meeting.
    AliskirenAmerican Society of Nephrologychronic kidney diseaseCKDhyperkalemiakidney failureKidney Week 2019 meetinglosartan
    Source : Kidney Week 2019 meeting

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok